Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates total enrolment at 750, including ...
The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed study. Read against the registry it is the sixth attempt to take a rare-disease drug into a large ...
OX40 atopic dermatitis development ended this month. Sanofi said on 24 July it will not file amlitelimab, four months after Kyowa Kirin halted every rocatinlimab trial on safety grounds. Both ...
Johnson & Johnson won a causation ruling. One week later it settled anyway. Understanding why explains everything else about this deal. The J&J talc settlement announced on 27 July 2026 commits $5.5 ...
Put this method on a file you are actually deciding. Witfire Elite provides pharmaceutical due diligence services built on the method used in every brief published here: every figure traced to a ...
Bright scientific image illustrating eplontersen TTR silencing in transthyretin amyloid cardiomyopathy, cardiac amyloid burden and the challenge of adding a silencer to stabilizer therapy. HELIOS-B ...
Merck priced the first oral PCSK9 inhibitor at $10.50 a tablet. Amgen has been selling Repatha, in cash, for roughly eight dollars a day since October. That is the whole trade in two lines, and most ...
Teva printed both halves of its own story and left them 40 pages apart. US generics fell $301M. Three branded products added roughly $306M. Put those side by side and the quarter explains itself.
A cinematic no-text visual of the Novo Nordisk–Eli Lilly lawsuit, using pharma injectables, medicine vials, legal scales, and blue-orange biotech lighting to show a high-stakes dispute in global ...
Witfire Elite · Cardiometabolic Risk Brief · Pricing & Access Oral PCSK9 Inhibitor Approved: LIPFENDRA Lists at $315. Repatha Already Sells for $239. The… ...
Witfire Elite · Cardiometabolic Risk Brief · Pricing & Access Oral PCSK9 Inhibitor Approved: LIPFENDRA Lists at $315. Repatha Already Sells for $239. The… ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results